All Oncology News

Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.

Fox Chase Cancer Center researchers showed that in men who underwent prostate cancer surgery, urinary sphincter function improved with adjuvant radiation.

NVL-655 has received FDA breakthrough therapy designation for patients with pretreated ALK-positive non-small cell lung cancer.

To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.

Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive subcutaneous immunotherapy at home.

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

The FDA has granted accelerated approval to tarlatamab for the treatment of patients with ES-SCLC with disease progression on or after platinum-based chemotherapy.

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

The FDA will hold an end-of-phase 2 meeting to discuss botensilimab plus balstilimab for the treatment of patients with relapsed/refractory metastatic colorectal cancer.

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

Seeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.

Bruna Pellini, MD, highlights the multiple immunotherapies currently available for patients with NSCLC in the perioperative setting and elucidates ctDNA’s role in the treatment paradigm.

Carol M. Mangione, MD, discusses the ramifications of the US Preventative Task Force’s April decision to update the breast cancer screening guidelines.

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

Pertuzumab plus trastuzumab produced antitumor activity and a mild adverse effect profile in patients with pretreated biliary tract cancer with ERBB2/3 alterations.

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

Samilia Obeng-Gyasi, MD, MPH, highlights a study on the association between neighborhood opportunity with all-cause mortality in patients with breast cancer.

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.

The FDA has approved one of the first HPV self-collection solutions, which can be used to identify women who are at risk of developing cervical cancer.

The National Cancer Institute has awarded “comprehensive cancer center” status to Georgetown University‘s Lombardi Comprehensive Cancer Center.

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.

Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.